Assessment of phosphatidylinositol-3 kinase (PI3K) as a prognostic marker in head and neck squamous cell carcinoma (HNSCC)

被引：1
|
作者：
Pectasides, E.
Founztilas, G.
Sasaki, C.
Burtness, B.
Psyrri, A.
机构：
[1] Yale Univ, New Haven, CT USA
[2] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17028
引用
收藏
页数：2
相关论文
共 50 条
  • [31] MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck
    Luangdilok, Sutima
    Box, Carol
    Harrington, Kevin
    Rhys-Evans, Peter
    Eccles, Suzanne
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (04) : 520 - 529
  • [32] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, Andrew J.
    DeGraff, William
    Choudhuri, Rajani
    Sowers, Anastasia L.
    Thetford, Angela
    Cook, John A.
    Van Waes, Carter
    Mitchell, James B.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2792 - 2801
  • [33] Tumor-specific PI3K inhibition via nanoparticle targeted delivery in head and neck squamous cell carcinoma
    Mizrachi, Aviram
    Shamay, Yosi
    Shah, Janki
    Brook, Samuel I.
    Soong, Joanne
    Rajasekhar, Vinagolu K.
    Humm, John L.
    Powell, Simon N.
    Baselga, Jose
    Heller, Daniel A.
    Haimovitz-Friedman, Adriana
    Scaltriti, Maurizio
    CANCER RESEARCH, 2017, 77
  • [34] EGFR/PI3K/AKT/MTOR PATHWAY IN HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENTS WITH DIFFERENT HPV STATUS
    Janecka-Widla, Anna
    Majchrzyk, Kaja
    Mucha-Malecka, Anna
    Biesaga, Beata
    POLISH JOURNAL OF PATHOLOGY, 2021, 72 (04) : 296 - 314
  • [35] Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma
    Burrows, F.
    Shivani, M.
    Wang, Z.
    Chan, S.
    Gilardi, M.
    Gutkind, S.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S43 - S44
  • [36] Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma
    Bernard, Monique
    Cardin, Guillaume B.
    Cahuzac, Maxime
    Ayad, Tareck
    Bissada, Eric
    Guertin, Louis
    Bahig, Houda
    Nguyen-Tan, Phuc Felix
    Filion, Edith
    Ballivy, Olivier
    Soulieres, Denis
    Rodier, Francis
    Christopoulos, Apostolos
    CANCERS, 2020, 12 (09) : 1 - 24
  • [37] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, A.
    DeGraff, W.
    Choudhuri, R.
    Sowers, A. L.
    Thetford, A.
    Cook, J. A.
    Van Waes, C.
    Mitchell, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S196 - S197
  • [38] A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
    Mazumdar, Tuhina
    Byers, Lauren A.
    Ng, Patrick Kwok Shing
    Mills, Gordon B.
    Peng, Shaohua
    Diao, Lixia
    Fan, You-Hong
    Stemke-Hale, Katherine
    Heymach, John V.
    Myers, Jeffrey N.
    Glisson, Bonnie S.
    Johnson, Faye M.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (11) : 2738 - 2750
  • [39] Targeting compensatory mechanisms of resistance to phosphatidylinositol 3-kinase inhibitors in head and neck squamous cell carcinoma
    Michmerhuizen, Nicole L.
    Leonard, Elizabeth
    Foltin, Susan K.
    Kulkarni, Aditi
    Carey, Thomas E.
    Bradford, Carol R.
    Jiang, Hui
    Brenner, Chad
    CANCER RESEARCH, 2017, 77
  • [40] HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines
    Elisabeth Foki
    Isabella Stanisz
    Lorenz Kadletz
    Ulana Kotowski
    Rudolf Seemann
    Rainer Schmid
    Gregor Heiduschka
    Wiener klinische Wochenschrift, 2021, 133 : 26 - 31
12345